FOXK2 and cancer: Consequently, this barrier has become a significant roadblock for the broader adoption of nucleotide‐based treatments.[27] Therefore, crafting a precise co‐delivery system for metformin and FOXK2 siRNA is crucial for tapping into their synergistic therapeutic potential against cancer.